Member Info for Goodbody

https://www.proactiveinvestors.co.uk/companies/stocktube/11098/bond-repayment-amendment-to-give-collagen-solutions-greater-flexibility-to-exploit-opportunities--11098.html

Great update. CE mark progressing well with no issues. New contracts and revenues on track. He sounds really positive about the progress and opportunities.

Very good RNS, revenues higher and more contracts being signed. Looking very promising for the second half of the year.

"We anticipate that we will have a significant year of growth and change, and it will be a transitional year in terms of new product development and revenue generation," the AIM-listed company said. http://www.lse.co.uk/sharecast-news-article.asp?shareprice=&ArticleCode=28154343&ArticleHeadline=Collagen_Solutions_CEO_to_present_update_at_biotech_showcase_next_month

Its also time for the october trading statement

they did say they would increase coms and visabilty so time for an update in my opinion. Agree CE update would be good. They said previously that they had done the audit. “ChondroMimetic® is on track for both CE Mark and first-in-man surgery in this financial year, following a successful audit by our notified body regulator” That appears to be part of step 6 of the process. https://www.emergobyul.com/resources/europe-process-chart Step 7 is the granting of CE marking.

https://www.hardmanandco.com/companies/collagen-solutions-plc/

https://depositormoney.com/bovine-based-collagen-for-biomedical-applications-market-to-reach-an-opportunity-of-us-1300-mn-by-2025/ Collagen for Biomedical Applications Market to Reach an Opportunity of US$ 1300 Mn by 2025 “The report also provides profiles of leading players operating in the global bovine-based collagen for biomedical applications market. Collagen Solutions LLP and Medtronic are the major players operating in the market, offering products with proprietary technologies.” “ In September 2015, Collagen Solutions acquired all assets and exclusive worldwide license from ChondroMimetic from Orthomimetics Limited and Cambridge Enterprise Ltd. ChondroMimetic is primarily a manufacturer of collagen-based implants utilized for the treatment of small osteochondral defects. This acquisition provided Collagen Solutions with official license to sell regenerative medical products in the orthobiologics market across the globe.”

And another 650k purchase by the Chairman this time Very confident/clear signal for what’s to come in my opinion.

All looking very positive, hopefully we get an operational update soon. Medica trade fair event coming up in november. Interims in december, so lots of news updates to come. Then we have the CE marking updates which could be huge by itself. Directors clearly positioning with stock purchases at market prices and future stock options.

50day moving average crosses 200day moving average today. Both up trending so looking very positive, especially with the very positive agm statement regarding progress and meeting market expectations.

Fundamentals looking very good now and so are technicals. 200day moving average has turned with a clear uptrend forming. 50day moving average should cross over the 200day in the next 5days forming a golden cross.

"We are on track to meet our key initiatives for the year, including achieving financial performance to bring us in line with market expectations. Our commercial execution plans are on track, including the recently announced signing of new distribution partners in China and new development agreements closed in the first quarter of this year that offset a previously announced specific risk with a Korean customer. ChondroMimetic® is on track for both CE Mark and first-in-man surgery in this financial year, following a successful audit by our notified body regulator this month. "We are currently in negotiations with multiple distributors in Europe, which we expect to conclude in parallel with the ChondroMimetic® CE Mark. We also recently completed the initial animal studies for our proprietary bone graft product that will support partner discussions at the upcoming North American Spine Society meeting in September. Operationally, our New Zealand restructuring initiative is delivering the expected synergies and benefits, as the assets related to collagen production and R&D have been relocated to the UK and USA respectively with operational setup and validation underway according to plan. The New Zealand team is now fully focused on the tissue business and has already identified several new customer opportunities. Finally, we will continue to deliver more visibility and metrics to our investors relating to the value and progress within our core business."

http://ir.collagensolutions.com/content/news/2018/210818.asp

http://www.proactiveinvestors.co.uk/companies/news/203275/collagen-solutions-inks-distribution-deals-with-two-new-chinese-partners

http://www.proactiveinvestors.co.uk/companies/news/203148/collagen-solutions-looks-to-have-put-last-years-difficulties-behind-it-with-strong-start-to-current-year-203148.html

Hopefully we will get some updates released in an AGM statement like last year.

Nice research paper on ChondroMimetic http://ir.collagensolutions.com/pdf/research/Hardman_Research_26Feb2018.pdf

This company looks to have a lot of support with 43% of stock in major shareholders hands and 17% with directors. Leaves only 40% for pi’s and thats assuming there aren’t other ii’s with smaller stakes.

Not long to go before operational updates and Q2 results. Q1 was cash positive with production at 1543bopd / $67 per barrel, so looking for considerable increases in cash flows given their production rate in april was 1772bopd and they were looking to ramp it up through the quarter; and oil has been around the $70-$75 range for the past three months.